Brain Tumor Treatment Market Size, Share, Growth, and Industry Analysis, By Type (Tissue Engineering,Immunotherapy,Gene Therapy,Other Therapies), By Application (Hospitals and Clinics,Treatment Center,Others), Regional Insights and Forecast to 2035

Brain Tumor Treatment Market Overview

The global Brain Tumor Treatment Market size is projected to grow from USD 3775.91 million in 2026 to USD 4280.75 million in 2027, reaching USD 12552.62 million by 2035, expanding at a CAGR of 13.37% during the forecast period.

The Brain Tumor Treatment Market has become one of the most critical areas in oncology as brain and central nervous system (CNS) cancers account for nearly 308,000 new cases globally in 2020, with over 251,000 deaths reported in the same year. Glioblastoma (GBM) alone accounts for about 48% of malignant brain tumors, with median survival remaining limited to 12–18 months despite treatment.

In the USA, approximately 25,000 cases of brain and other nervous system cancers are diagnosed annually, accounting for less than 2% of all cancers, yet responsible for over 18,000 deaths each year. Glioblastoma makes up nearly 13,000 cases annually, with over 10,000 deaths, highlighting its lethality.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Key Market Driver: More than 62% of oncologists report demand for improved survival outcomes as the primary driver, with nearly 70% of patients requiring multimodal treatment including surgery, radiation, and chemotherapy.
• Major Market Restraint: Around 45% of patients in low- and middle-income countries lack access to advanced radiotherapy and immunotherapy, while 38% of global patients discontinue treatment due to cost or access barriers.
• Emerging Trends: Over 30% of clinical trials since 2022 focus on immunotherapies, while 20% target gene therapies and 15% explore tumor-treating fields, reflecting diverse innovation pipelines.
• Regional Leadership: North America holds 38% of clinical trials, Europe 32%, and Asia-Pacific 25%, with the remainder distributed across Latin America, Middle East, and Africa.
• Competitive Landscape: The top 10 pharmaceutical and biotech companies account for over 55% of late-stage pipeline therapies, with two companies alone controlling more than 25% of targeted therapy trials.
• Market Segmentation: Hospitals and clinics account for 90% of treatment delivery, treatment centers about 7%, and other applications including research institutions and palliative care about 3%.
• Recent Development: Between 2023 and 2025, more than 15 new therapies entered phase II/III trials, and two targeted drugs achieved regulatory approval, expanding available treatment options.

Brain Tumor Treatment Market Latest Trends

The Brain Tumor Treatment Market is undergoing transformative shifts as precision medicine, immunotherapy, and non-invasive technologies gain traction. In 2023, more than 120 active global clinical trials investigated advanced treatment methods such as checkpoint inhibitors, CAR-T therapy, tumor-treating fields, and mRNA-based vaccines.

Brain Tumor Treatment Market Dynamics

The Brain Tumor Treatment Market Dynamics are shaped by a mix of clinical demand, scientific innovation, and persistent barriers. The most significant driver is the rising global incidence of brain tumors, with more than 308,000 new cases and 251,000 deaths worldwide reported in 2020. Glioblastoma, the most aggressive form, accounts for nearly 48% of malignant brain tumors and has a median survival rate of only 12–18 months despite combined surgery, radiotherapy, and chemotherapy.

DRIVER

"Rising demand for innovative oncology treatments."

The Brain Tumor Treatment Market Growth is fueled by increasing global incidence and high unmet medical needs. Each year, approximately 308,000 new cases of brain and CNS cancers are diagnosed, with glioblastoma accounting for nearly 48% of malignant tumors. Rising survival expectations, greater healthcare spending, and over 100 active clinical trials for novel therapies contribute to adoption.

RESTRAINT

"Limited access and affordability challenges."

Despite innovation, affordability and access remain critical barriers. Nearly 45% of global patients lack access to radiotherapy, and over 50% cannot access immunotherapy or advanced drugs in low-income regions. Treatment discontinuation rates exceed 38% due to cost or side effects. Moreover, therapies like CAR-T cells cost hundreds of thousands of dollars, making them available to only a small percentage of patients in high-income countries.

OPPORTUNITY

"Growth in personalized and precision medicine."

Personalized medicine offers major opportunities. Over 70% of gliomas are now molecularly profiled for IDH1/2, MGMT methylation, or EGFR amplification, guiding targeted therapies. With more than 15 new drugs in phase II/III trials, including vaccines and inhibitors, expansion into biomarker-driven therapies could increase patient survival by 20–30% in certain groups.

CHALLENGE

"Biological barriers and tumor resistance."

The blood–brain barrier prevents more than 95% of small-molecule drugs from reaching brain tumors, complicating treatment. Resistance is another challenge; glioblastoma recurrence occurs in over 80% of patients even after surgery, chemotherapy, and radiotherapy. Additionally, clinical trial attrition remains high, with less than 10% of experimental brain tumor drugs achieving late-stage approval.

Brain Tumor Treatment Market Segmentation

The Brain Tumor Treatment Market Segmentation illustrates distinct adoption patterns across therapies and care settings. By type, the market includes tissue engineering, immunotherapy, gene therapy, and other modalities such as tumor-treating fields and minimally invasive procedures. Tissue engineering represents about 15% of experimental therapies, with more than 20 global trials testing stem-cell-based and scaffold approaches.

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

BY TYPE

Tissue Engineering:  Tissue engineering in brain tumor treatment is growing with innovations in stem cell therapies, scaffolds, and regenerative methods. Over 20 global trials tested engineered tissues for tumor repair. Around 15% of experimental therapies in this category aim to restore brain function post-resection.

The global Tissue Engineering segment within the Brain Tumor Treatment Market is projected at USD 537.28 million in 2025, holding 15.0% of the global share, and is expected to reach USD 1,660.83 million by 2034, advancing at a CAGR of 13.37%, driven by regenerative techniques, stem-cell innovations, and scaffolding technologies that improve post-surgical recovery and tumor site repair.

Top 5 Major Dominant Countries in the Tissue Engineering Segment

• United States: The United States Tissue Engineering market is valued at USD 188.05 million in 2025, accounting for 35.0% share, projected to achieve USD 581.29 million by 2034 at a 13.38% CAGR, supported by extensive research infrastructure and leading regenerative medicine centers.
• Germany: Germany’s Tissue Engineering market is estimated at USD 80.59 million in 2025, with 15.0% share, forecasted at USD 249.12 million by 2034 at 13.37% CAGR, reflecting strong adoption across university hospitals and research-driven collaborations.
• China: China’s Tissue Engineering market is projected at USD 74.68 million in 2025, representing 13.9% share, expected to reach USD 230.72 million by 2034 at a CAGR of 13.36%, driven by increasing clinical trials and advanced cell-based therapies.
• Japan: Japan’s Tissue Engineering segment is valued at USD 58.90 million in 2025, equating to 11.0% share, and is forecasted to reach USD 181.00 million by 2034 at a 13.37% CAGR, supported by high investments in regenerative medicine.
• France: France’s Tissue Engineering market is estimated at USD 53.73 million in 2025, with 10.0% share, projected to achieve USD 165.95 million by 2034, expanding at a CAGR of 13.36%, led by academic hospitals adopting tissue repair therapies.

Immunotherapy: Immunotherapy dominates innovation, accounting for 30% of clinical trials since 2022. CAR-T therapies showed tumor shrinkage in 62% of glioblastoma patients, while checkpoint inhibitors improved survival rates in select subgroups by 15–20%.

The Immunotherapy segment is valued at USD 1,252.58 million in 2025, commanding 35.0% of the global market share, and is expected to reach USD 3,875.29 million by 2034, growing at a CAGR of 13.37%, supported by checkpoint inhibitors, CAR-T cell therapies, and vaccine-based treatments that deliver survival benefits for aggressive tumors.

Top 5 Major Dominant Countries in the Immunotherapy Segment

• United States: The US Immunotherapy market is projected at USD 563.66 million in 2025, holding 45.0% share, expected to achieve USD 1,743.88 million by 2034 at 13.38% CAGR, driven by more than 50 ongoing clinical trials in brain tumor immunotherapy.
• United Kingdom: The UK Immunotherapy market is valued at USD 137.78 million in 2025, representing 11.0% share, forecasted to reach USD 426.28 million by 2034, advancing at 13.37% CAGR, supported by strong national cancer research programs.
• Germany: Germany’s Immunotherapy segment is estimated at USD 125.26 million in 2025, with 10.0% share, projected at USD 387.53 million by 2034, expanding at a 13.36% CAGR, reflecting strong integration in advanced oncology centers.
• China: China’s Immunotherapy market is forecasted at USD 112.73 million in 2025, equating to 9.0% share, and expected to reach USD 348.78 million by 2034, advancing at 13.37% CAGR, fueled by large-scale oncology research and expanding clinical trials.
• Japan: Japan’s Immunotherapy market is valued at USD 100.20 million in 2025, representing 8.0% share, forecasted to achieve USD 309.92 million by 2034 at 13.37% CAGR, with rising adoption of checkpoint inhibitors and CAR-T research.

Gene Therapy: Gene therapy represents about 20% of the pipeline, with IDH1/2 inhibitors and viral vectors showing promise. Trials for vorasidenib improved progression-free survival from 11.1 months to 27.7 months in low-grade glioma patients.

The Gene Therapy segment is forecasted at USD 894.70 million in 2025, representing 25.0% share, and is expected to reach USD 2,768.07 million by 2034, advancing steadily at a CAGR of 13.37%, supported by IDH1/2 inhibitors, viral vector therapies, and experimental gene editing solutions.

Top 5 Major Dominant Countries in the Gene Therapy Segment

• United States: The US Gene Therapy market is projected at USD 357.88 million in 2025, holding 40.0% share, expected to achieve USD 1,107.23 million by 2034 at 13.37% CAGR, driven by FDA approvals and late-stage trials.
• China: China’s Gene Therapy market is estimated at USD 125.26 million in 2025, representing 14.0% share, forecasted to reach USD 387.53 million by 2034, expanding at 13.36% CAGR, with increasing investments in oncology genomics.
• Germany: Germany’s Gene Therapy segment is forecasted at USD 107.36 million in 2025, equating to 12.0% share, expected to achieve USD 332.16 million by 2034 at 13.37% CAGR, reflecting strong participation in multinational trials.
• Japan: Japan’s Gene Therapy market is projected at USD 89.47 million in 2025, with 10.0% share, forecasted to reach USD 276.81 million by 2034, growing at 13.36% CAGR, led by expanding gene therapy research in oncology centers.
• France: France’s Gene Therapy segment is valued at USD 71.57 million in 2025, representing 8.0% share, expected to achieve USD 221.45 million by 2034, advancing at 13.37% CAGR, supported by academic partnerships in molecular oncology.

Other Therapies: Tumor-treating fields (TTF) are expanding rapidly, used in 20,000+ patients worldwide, with survival benefit of 5–6 months in glioblastoma. MRI-guided laser ablation and proton therapy are additional modalities, representing about 10% of new therapies.

The Other Therapies segment is projected at USD 894.24 million in 2025, holding 25.0% share, and expected to reach USD 2,767.93 million by 2034, advancing at a CAGR of 13.37%, supported by tumor-treating fields, proton therapy, and minimally invasive surgical approaches.

Top 5 Major Dominant Countries in the Other Therapies Segment

• United States: The US market for Other Therapies is projected at USD 357.70 million in 2025, holding 40.0% share, forecasted to achieve USD 1,107.17 million by 2034 at 13.37% CAGR, with adoption of tumor-treating fields in more than 10,000 patients.
• Japan: Japan’s Other Therapies segment is forecasted at USD 134.13 million in 2025, equating to 15.0% share, expected to reach USD 415.18 million by 2034, advancing at 13.37% CAGR, supported by adoption of proton therapy and minimally invasive methods.
• Germany: Germany’s Other Therapies market is projected at USD 125.26 million in 2025, representing 14.0% share, and expected to achieve USD 387.53 million by 2034, growing at 13.36% CAGR, supported by strong proton therapy expansion.
• China: China’s Other Therapies market is valued at USD 98.37 million in 2025, holding 11.0% share, forecasted at USD 304.47 million by 2034, advancing at 13.37% CAGR, driven by investment in radiation and advanced oncology technologies.
• United Kingdom: The UK market for Other Therapies is projected at USD 80.48 million in 2025, equating to 9.0% share, forecasted at USD 249.11 million by 2034, expanding at 13.37% CAGR, with adoption across national oncology hospitals.

BY APPLICATION

Hospitals and Clinics: Represent about 90% of treatment delivery, with over 15,000 brain tumor resections annually in the USA alone, and thousands more radiotherapy and chemotherapy cycles globally. Hospitals integrate both standard and advanced therapies.

The Hospitals and Clinics segment is valued at USD 2,684.10 million in 2025, representing 75.0% share, expected to reach USD 8,304.20 million by 2034, advancing at a CAGR of 13.37%, as hospitals remain the core providers of brain tumor resections, chemotherapy, and radiotherapy.

Top 5 Major Dominant Countries in the Hospitals & Clinics Application

• United States: USD 1,073.64 million in 2025, 40.0% share, forecasted at USD 3,321.68 million by 2034, CAGR 13.37%, supported by more than 700 neurosurgical hospitals and nationwide adoption of immunotherapy.
• China: USD 402.62 million in 2025, 15.0% share, expected to reach USD 1,243.63 million by 2034, CAGR 13.36%, driven by national oncology hospitals and growing neurosurgery programs.
• Germany: USD 268.41 million in 2025, 10.0% share, projected at USD 828.84 million by 2034, CAGR 13.37%, supported by integrated oncology hospitals.
• Japan: USD 268.41 million in 2025, 10.0% share, expected to achieve USD 828.84 million by 2034, CAGR 13.37%, driven by advanced oncology centers.
• India: USD 134.20 million in 2025, 5.0% share, forecasted at USD 414.20 million by 2034, CAGR 13.36%, reflecting rapid hospital expansion.

Treatment Centers: Account for 7% of applications, focusing on advanced gene therapy, immunotherapy, and experimental treatments. More than 20 specialized oncology centers worldwide now offer CAR-T or vaccine-based brain tumor therapy.

The Treatment Centers segment is projected at USD 537.28 million in 2025, holding 15.0% global share, and is expected to reach USD 1,660.83 million by 2034, advancing at 13.37% CAGR, with specialized centers leading adoption of CAR-T, vaccines, and gene therapies.

Top 5 Major Dominant Countries in the Treatment Centers Application

• United States: USD 214.91 million in 2025, 40.0% share, forecasted at USD 664.33 million by 2034, CAGR 13.37%, supported by national cancer research institutes.
• Germany: USD 80.59 million in 2025, 15.0% share, projected at USD 249.12 million by 2034, CAGR 13.36%, reflecting adoption of CAR-T centers.
• China: USD 74.68 million in 2025, 13.9% share, forecasted at USD 230.72 million by 2034, CAGR 13.37%, supported by expanding oncology hubs.
• Japan: USD 53.73 million in 2025, 10.0% share, projected at USD 165.95 million by 2034, CAGR 13.36%, with specialized centers integrating advanced immunotherapy.
• United Kingdom: USD 53.73 million in 2025, 10.0% share, forecasted at USD 165.95 million by 2034, CAGR 13.37%, supported by oncology trial hubs.

Others: Represent 3% of the market, including palliative care and research centers. More than 30 early-phase gene therapy trials for brain tumors are being conducted annually across smaller research institutions.

The Others segment of the Brain Tumor Treatment Market is valued at USD 357.88 million in 2025, representing 10.0% of the global share, and is forecasted to reach USD 1,107.23 million by 2034, advancing at a CAGR of 13.37%, strongly supported by research units, academic oncology institutions, and palliative care providers that are increasingly offering participation in clinical trials and expanding supportive services for brain tumor patients across both developed and emerging economies.

Top 5 Major Dominant Countries in the Others Application

• United States: The United States leads the Others application segment with a market size of USD 143.15 million in 2025, holding a 40.0% share, and is projected to reach USD 443.0 million by 2034 at a CAGR of 13.37%, driven by the presence of hundreds of academic research institutions and oncology centers actively running brain tumor trials, with significant participation from both public and private healthcare networks.
• China: China’s Others application market is valued at USD 53.68 million in 2025, representing a 15.0% share, and is forecasted to expand to USD 165.92 million by 2034 at a CAGR of 13.36%, supported by the rapid establishment of research hospitals and national cancer programs that focus on experimental therapies, early detection methods, and integration of molecular oncology in treatment centers.
• Germany: Germany contributes significantly to the Others application segment with a market size of USD 35.78 million in 2025, holding 10.0% share, and is expected to achieve USD 110.72 million by 2034, advancing at a CAGR of 13.37%, reflecting the country’s strong national cancer research programs, well-developed trial infrastructure, and the presence of specialized institutes focusing on glioblastoma and rare brain tumors.
• Japan: Japan’s Others application market is forecasted at USD 35.78 million in 2025, equating to a 10.0% share, projected to reach USD 110.72 million by 2034 at a CAGR of 13.36%, supported by leading university trial centers and medical research institutes that continue to explore advanced experimental treatments and cutting-edge supportive care methods for patients with brain tumors.
• India: India’s Others application segment is valued at USD 17.89 million in 2025, representing a 5.0% share, and is forecasted to grow to USD 55.36 million by 2034 at a CAGR of 13.37%, supported by the rapid expansion of emerging oncology laboratories, increasing participation in global research collaborations, and growing focus on providing affordable clinical trial access for patients in both urban and semi-urban regions.

Regional Outlook for the Brain Tumor Treatment Market

The Brain Tumor Treatment Market Outlook demonstrates clear regional differences shaped by incidence, treatment infrastructure, and adoption of innovative therapies. North America remains the leading region, with the USA alone reporting nearly 25,000 new brain and nervous system cancer cases annually, supported by more than 700 neurosurgical centers and accounting for approximately 38% of global clinical trials.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

NORTH AMERICA

The Brain Tumor Treatment Market in North America is highly advanced, with 25,000 annual cases in the USA alone, supported by 700+ neurosurgical centers and over 15,000 radiotherapy procedures annually. North America represents nearly 38% of global clinical trials, with more than 50 ongoing CAR-T, checkpoint inhibitor, and targeted therapy studies.

The North America Brain Tumor Treatment Market is projected to reach USD 1,287.07 million in 2025, accounting for 36.0% of the global market share, and is forecasted to achieve USD 3,984.01 million by 2034, expanding steadily at a CAGR of 13.37%.

North America – Major Dominant Countries in the Brain Tumor Treatment Market

• United States: The United States dominates the North America market with an estimated size of USD 901.0 million in 2025, holding a commanding 70.0% share, projected to reach USD 2,788.8 million by 2034 at a CAGR of 13.37%, supported by more than 700 neurosurgical hospitals, ongoing FDA-approved trials, and advanced integration of immunotherapy treatments.
• Canada: Canada’s market is valued at USD 193.06 million in 2025, representing 15.0% share, and is expected to achieve USD 597.60 million by 2034 at a CAGR of 13.36%, reflecting the adoption of proton therapy, national cancer programs, and strong collaborations between academic institutions and healthcare providers.
• Mexico: Mexico’s market is projected at USD 96.53 million in 2025, accounting for 7.5% share, forecasted to reach USD 298.8 million by 2034 at a CAGR of 13.37%, supported by growing access to advanced neurosurgery and cross-border collaborations with US oncology centers.
• Brazil: Brazil’s market is estimated at USD 64.35 million in 2025, holding 5.0% share, expected to reach USD 199.2 million by 2034 at a CAGR of 13.36%, reflecting investments in advanced oncology infrastructure, expanded immunotherapy availability, and public healthcare initiatives.
• Others: Regional markets in North America are collectively valued at USD 32.17 million in 2025, contributing 2.5% share, and forecasted to achieve USD 99.6 million by 2034 at a CAGR of 13.37%, supported by smaller hospitals and specialized treatment centers.

EUROPE

Europe accounts for around 30% of global incidence, with nearly 65,000 annual cases of brain and CNS cancers. More than 200 hospitals perform neurosurgical resections, and radiotherapy is widely available. Survival outcomes mirror North America, though innovation adoption is slower.

The Europe Brain Tumor Treatment Market is forecasted at USD 1,037.25 million in 2025, representing 29.0% share of the global market, and is projected to reach USD 3,211.0 million by 2034, advancing at a CAGR of 13.37%, supported by national healthcare systems, widespread access to radiotherapy, and strong oncology research collaborations across academic and pharmaceutical institutions.

Europe – Major Dominant Countries in the Brain Tumor Treatment Market

• Germany: Germany leads Europe with a market value of USD 311.18 million in 2025, holding 30.0% share, forecasted to reach USD 963.3 million by 2034 at a CAGR of 13.37%, supported by over 80 neuro-oncology centers and advanced clinical trial participation.
• France: France’s market is valued at USD 207.45 million in 2025, representing 20.0% share, projected to achieve USD 642.2 million by 2034 at a CAGR of 13.36%, supported by nationwide immunotherapy adoption and advanced research institutes.
• United Kingdom: The UK’s market is projected at USD 155.59 million in 2025, holding 15.0% share, expected to reach USD 481.6 million by 2034 at a CAGR of 13.37%, driven by National Health Service funding and strong participation in oncology trials.
• Italy: Italy’s market is forecasted at USD 103.73 million in 2025, with 10.0% share, projected to achieve USD 321.1 million by 2034 at a CAGR of 13.36%, supported by expanding radiotherapy facilities and advanced neuro-oncology research.
• Spain: Spain’s market is valued at USD 103.73 million in 2025, equating to 10.0% share, forecasted at USD 321.1 million by 2034, growing at 13.37% CAGR, supported by increased oncology investments and medical infrastructure.

ASIA-PACIFIC

Asia-Pacific contributes to 40% of the global population, with rising incidence translating to over 100,000 new brain tumor cases annually. Japan and China lead adoption, with Japan operating 300+ neuro-oncology centers and China rapidly expanding radiotherapy capacity. India reports over 20,000 new cases annually, with increasing urban access to advanced therapies.

The Asia Brain Tumor Treatment Market is valued at USD 895.58 million in 2025, accounting for 25.0% of the global share, and is expected to reach USD 2,768.07 million by 2034, advancing at a CAGR of 13.37%, supported by rapid urbanization, rising healthcare investments, and increasing patient volumes across China, Japan, India, South Korea, and Australia.

Asia – Major Dominant Countries in the Brain Tumor Treatment Market

• China: China dominates Asia with a market value of USD 268.67 million in 2025, representing 30.0% share, projected to achieve USD 829.2 million by 2034 at a CAGR of 13.37%, supported by more than 200 oncology hospitals and government-backed clinical trials.
• Japan: Japan’s market is valued at USD 179.12 million in 2025, accounting for 20.0% share, forecasted at USD 552.6 million by 2034 at a CAGR of 13.36%, supported by more than 300 neuro-oncology centers and advanced regenerative medicine research.
• India: India’s market is projected at USD 134.34 million in 2025, holding 15.0% share, expected to reach USD 414.2 million by 2034 at a CAGR of 13.37%, supported by rapid expansion of specialized oncology hospitals.
• South Korea: South Korea’s market is forecasted at USD 134.34 million in 2025, representing 15.0% share, expected to achieve USD 414.2 million by 2034 at a CAGR of 13.36%, supported by rapid adoption of immunotherapy and advanced imaging technologies.
• Australia: Australia’s market is valued at USD 89.56 million in 2025, accounting for 10.0% share, forecasted at USD 276.8 million by 2034 at a CAGR of 13.37%, supported by precision medicine growth and advanced neurosurgical centers.

MIDDLE EAST & AFRICA

The Middle East & Africa lag with fewer than 10 specialized neuro-oncology centers per 100 million people in many countries. Annual incidence is underreported but estimated at 15,000–20,000 cases regionally. Access to advanced therapy is limited, with most patients treated via surgery and chemotherapy in urban centers.

The Middle East & Africa Brain Tumor Treatment Market is projected at USD 358.0 million in 2025, representing 10.0% of the global market, and is expected to reach USD 1,107.2 million by 2034, expanding at a CAGR of 13.37%, supported by expanding oncology access, government-backed investments, and the increasing adoption of advanced treatment options.

Middle East & Africa – Major Dominant Countries in the Brain Tumor Treatment Market

• Saudi Arabia: Saudi Arabia leads with a market size of USD 107.4 million in 2025, holding 30.0% share, forecasted to reach USD 332.2 million by 2034 at a CAGR of 13.37%, supported by government-backed oncology investments.
• United Arab Emirates: The UAE’s market is valued at USD 71.6 million in 2025, representing 20.0% share, projected to achieve USD 221.4 million by 2034 at a CAGR of 13.36%, supported by advanced private healthcare investments and rapid adoption of new oncology drugs.
• South Africa: South Africa’s market is forecasted at USD 53.7 million in 2025, with 15.0% share, expected to reach USD 165.9 million by 2034 at a CAGR of 13.37%, reflecting expansion of oncology centers.
• Egypt: Egypt’s market is estimated at USD 35.8 million in 2025, representing 10.0% share, projected to reach USD 110.7 million by 2034 at a CAGR of 13.36%, supported by public-private cancer initiatives.
• Others: Other Middle East & African countries collectively hold a market size of USD 89.5 million in 2025, representing 25.0% share, and are expected to reach USD 276.8 million by 2034, advancing at 13.37% CAGR, with improving oncology access.

List of Top Brain Tumor Treatment Companies

• Pfizer, Inc.
• Novartis AG
• Merck & Co.
• Reddy’s Laboratories Ltd
• Antisense Pharma
• Macleods Pharmaceutical Limited
• AstraZeneca plc
• Bristol Myers Squibb
• Hoffmann-La Roche
• Genentech U.S.A.
• Mankind Pharma

Roche/Genentech: Controls more than 15% of global targeted therapy trials in brain tumors, including multiple immunotherapy and checkpoint inhibitor programs.

Novartis AG: Holds approximately 12% share, with leading roles in CAR-T therapies and targeted drugs for IDH1/2 mutations.

Investment Analysis and Opportunities

Investments in the Brain Tumor Treatment Market are rising sharply, with more than USD 5 billion committed globally to oncology R&D annually, and brain tumor programs now representing about 8–10% of oncology pipelines. Venture capital funding for biotech start-ups focusing on immunotherapy and gene therapy exceeded USD 1 billion in 2023, with over 50 companies receiving funding for CNS tumor-specific therapies.

New Product Development

The Brain Tumor Treatment Market is witnessing robust product innovation. In 2024, the FDA approved vorasidenib, the first IDH1/2 inhibitor for low-grade gliomas, improving progression-free survival from 11.1 to 27.7 months. Tumor-treating fields devices now treat 20,000+ patients globally, with new portable systems reducing patient burden. CAR-T therapies are progressing, with one trial reporting tumor reduction in 62% of patients with recurrent glioblastoma.

Five Recent Developments

• FDA approval of vorasidenib in 2024 for IDH1/2-mutant gliomas, improving progression-free survival to 27.7 months versus 11.1 months placebo.
• CAR-T therapy trial in 2023 reported tumor shrinkage in 62% of glioblastoma patients with measurable tumors.
• Tumor-treating fields adoption surpassed 20,000 patients worldwide in 2024.
• Launch of 30+ mRNA-based vaccines in phase I/II clinical trials by biotech firms targeting glioblastoma.
• Expansion of proton therapy, with 100+ global centers offering precision radiation for brain tumors by 2025.

Report Coverage of Brain Tumor Treatment Market

The Brain Tumor Treatment Market Report provides comprehensive coverage of incidence, treatment modalities, pipeline therapies, and adoption across hospitals, treatment centers, and research institutions. The report includes analysis of global incidence of 308,000 cases annually, treatment statistics such as 15,000+ surgeries annually in the USA, and survival outcomes across modalities. It highlights major therapeutic approaches including surgery, radiotherapy, chemotherapy, immunotherapy, gene therapy, and tumor-treating fields, with facts on clinical trials, patient populations, and technology adoption.

Brain Tumor Treatment Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 3775.91 Million in 2026
Market Size Value By	USD 12552.62 Million by 2035
Growth Rate	CAGR of 13.37% from 2026 - 2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : Tissue Engineering Immunotherapy Gene Therapy Other Therapies By Application : Hospitals and Clinics Treatment Center Others
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample